Significance of cytogenetic abnormalities in acute myeloid leukaemia by Harani, Mahadev S. et al.
eCommons@AKU
Department of Pathology and Laboratory Medicine Medical College, Pakistan
January 2006
Significance of cytogenetic abnormalities in acute
myeloid leukaemia
Mahadev S. Harani
Chandka Medical College
Salman Adil
Aga Khan University, salman.adil@aku.edu
Ghulam Nabi Kakepoto
Aga Khan University
Zahida Khilji
Aga Khan University
Usman Shaikh
Aga Khan University
See next page for additional authors
Follow this and additional works at: http://ecommons.aku.edu/
pakistan_fhs_mc_pathol_microbiol
Part of the Pathology Commons
Recommended Citation
Harani, M., Adil, S., Kakepoto, G., Khilji, Z., Shaikh, U., Khurshid, M. (2006). Significance of cytogenetic abnormalities in acute
myeloid leukaemia. Journal of Pakistan Medical Association, 56(1), 9-13.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/553
Authors
Mahadev S. Harani, Salman Adil, Ghulam Nabi Kakepoto, Zahida Khilji, Usman Shaikh, and Mohammad
Khurshid
This article is available at eCommons@AKU: http://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/553
Introduction
Chromosomal abnormalities are valuable in the
diagnosis and prognosis of different types of leukaemia and
lymphoma. Many of these abnormalities are uniquely asso-
ciated with specific histologic or immunologic subtypes of
malignant haematological disorders.1 However, presenta-
tion cytogenetics is widely recognized as one of the most
important prognostic determinants in acute myeloid
leukaemia (AML).2 Substantial heterogeneity exists among
patients with acute myeloid leukaemia which can be detect-
ed morphologically3 and with improved cytogenetic tech-
niques.4 During the last two decades the clinical importance
of both cytogenetic and molecular genetic analysis has
become increasingly important in determining prognosis in
AML. The identification of specific chromosomal abnor-
malities and their correlation with cytomorphologic fea-
tures, immunophenotype and clinical outcome have led to
new understanding of AML as a heterogeneous disease.5
Recently in the new classification of haematological malig-
nancies by World Health Organization (WHO), specific
cytogenetic abnormalities have been used to help define dis-
tinct disease entities among myeloid disorders.6
Several factors have been described to have prog-
nostic significance in AML like patient characteristics such
as age, performance status, adequacy of organ function and
disease characteristics and at that same time, the clinical
significance of cytogenetic aberration has become increas-
ingly appreciated.7 Certain changes are highly correlated
with particular FAB subgroups of AML, such as t(8;21) and
M2, t(15;17) and M3, inv16 and M4 Eo, t(9; 11) and M5a,
and t(1; 22) and M7.8 Recent reports suggest that the use of
high resolution methods to study the banding pattern in
extended chromosomes discloses that 90% of patients have
an abnormal karyotype.4 To date, over 160 structural chro-
mosome abnormalities have been reported in hematological
malignancies.9
These recurring abnormalities have an important and
independent impact on the prognosis, and they may influ-
ence the management of disease. New techniques such as
fluorescence in situ hybridization (FISH), Southern blot,
polymerase chain reaction, and gene expression profiling
have also added important information to the more sophis-
ticated sub grouping of AML.5 With optimal application of
these techniques in the diagnosis of acute leukemias, the
treatment strategies can be more specifically directed and
Original Article
Significance of Cytogenetic Abnormalities in Acute Myeloid Leukaemia
Mahadev S. Harani1, Salman N Adil2, Ghulam Nabi Kakepoto2, Zahida Khilji2, Usman Shaikh2, Mohammad Khurshid2
Department of Pathology, Chandka Medical College, Larkana1, Department of Pathology and Microbiology, Aga Khan University2, Karachi.
Abstract
Objective: To evaluate the role of karyotype in acute myeloid leukaemia (AML) as a predictor of response to
induction chemotherapy.
Methods: A cross-sectional study was carried out at the department of Pathology and Oncology, Aga Khan
University Karachi from January 2003 to January 2005. Newly diagnosed patients with denovo AML admitted to
the hospital were included in the study. Diagnosis of AML was based on FAB criteria, immunophenotyping and
cytogenetic studies. They were treated according to standard protocols (combination of anthracycline and cytara-
bine -3+7) and those who had acute promyelocytic leukaemia additionally received all- trans retinoic acid
(ATRA). 
Results: A total of 56 patients were enrolled, 4 were excluded due to inadequate cytogenetic analysis and the
remaining patients entered the study protocol. There were 32 males and 20 females with mean age of 31.3 years
(range 9 months to 73 years). Thirty-five (67.3%) patients had normal karyotype while 17 (32.7%) were found to
have cytogenetic abnormalities. Eleven patients did not receive treatment at our hospital. Half of the (51.2%)
patients out of remaining 41 achieved complete remission on bone marrow examination after receiving induction
chemotherapy. In favourable risk group 3/3 (100%) achieved complete remission (CR) while 15/32 (46.9%) in
intermediate risk group and 3/6 (50%) in unfavourable risk group. There was low CR rate in patients with high
white cell counts.
Conclusion: The frequency of cytogenetic abnormalities in AML and response to induction chemotherapy was
low when compared with international data possibly due to the small sample size. However, there was a clear
difference in CR rates between favourable and unfavourable risk groups (JPMA 56:9;2006).
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new therapeutic approaches can be evaluated more effec-
tively.10
Keeping in view the diagnostic and prognostic sig-
nificance of cytogenetic abnormalities, we report cytogenet-
ic findings in 52 AML patients seen at our institution from
January 2003 to January 2005, and to determine the impact
of karyotype as a prognostic factor for response of induction
chemotherapy. 
Patients and Methods
A cross sectional study was carried out at the depart-
ment of Pathology and Oncology, Aga Khan University
Karachi (AKUH).
Consecutive patients admitted to the hospital with all of
the following criteria were included in the study:
(a) Diagnosis of AML made between January 2003 to
January 2005; (b) all age groups; (c) absence of prior his-
tory of malignant disease, cytotoxic or radiation therapy,
myelodysplasia and (d) Submission of bone marrow sam-
ple for cytogenetic analysis before initiation of therapy.
Patients were treated according to standard protocol
of induction chemotherapy with cytosine arabinoside for 7
days and anthracycline for 3 days. Seven patients with M3
FAB subtype received all-trans retinoic acid (ATRA) in con-
junction with chemotherapy for induction of remission.
Remission status was checked after 4 weeks of induction
chemotherapy. Informed consent was obtained from
patients or parents as appropriate.
The diagnosis of AML was based on morphologic
and cytochemical studies of peripheral blood smears and
bone marrow aspirate obtained before therapy was initiated.
FAB criteria were used for classification and subclassifica-
tion of the disorder5 and reviewed by two independent
observers who lacked knowledge of cytogenetics results.
All the peripheral blood and bone marrow films were
stained with Leishman's stain. Additionally following cyto-
chemical stains were used: periodic acid-Schiff (PAS)
reagent, Myeloperoxidase (MPO), Sudan Black B (SBB)
and a-naphthyl acetale esterase (ANAE).
Immunophenotyping was done in some cases where consid-
ered essential. Haematological parameters were obtained by
Coulter Cell Counter.
Cytogenetic analysis was performed using a
Trypsin-Giemsa banding technique.11 Cells were obtained
from aspirated bone marrow before therapy was initiated.
Metaphase cells were examined from direct preparations
and/ or short-term (24-, 48-, and 72-h) unstimulated cul-
tures. Whenever possible, at least 20 mitosis were analyzed.
Karyotypes were interpreted using International System for
Cytogenetic Nomenclature (1995) criteria.12
Cytogenetic abnormalities were grouped according
to published criteria adopted by Southwest Oncology Group
(SWOG) into favourable, intermediate and unfavourable
risk categories.11
Bone marrow was performed after 4 weeks of induc-
tion chemotherapy to determine the remission status.
Complete remission (CR) was defined either as a normocel-
lular bone marrow aspirate containing less than 5% blast
cells and absence of Auer rods with evidence of normal
maturation of other marrow elements or the bone marrow
biopsy with more than 20% cellularity and maturation of all
cell lines having less than 5% blast cells. Full recovery of
normal peripheral blood count is not required to define
CR.2,13 Remission failures were classified as deaths due to
induction chemotherapy within 30 days or persistent disease
showing more than 5% blast cells in bone marrow at the end
of 30 days.
The data was analyzed using SPSS software (version
12.0.1). The following variables were studied for their prog-
nostic value on the achievement for CR: age, sex, haemo-
globin level, white cell count, platelet count and karyotype.
Mann-Whitney U test and Chi-Square test were used to see
the association between variables.
Results
A total of 56 patients were seen, 4 patients having
inadequate samples for complete cytogenetic analysis were
excluded from study. Out of 52 patients that were studied,
32 were males and 20 were females with a male to female
ratio of 1.6:1. Their ages ranged between 9 months to 73
years. The mean haemoglobin concentration was 8.6g/dl
(range 3.4-12.4), mean white cell count was 37.3x109/L
(range 1.3-168.3), and mean platelet count was 34.3x109/L
(range 1-180). The frequency of various FAB types is
shown in Figure.
Of the 52 patients with adequate samples, 35
(67.3%) had a normal karyotype, and 17 (32.7%) had 
M 5, n=5
M 4Eo , n=6
M 4, n=19
M 3, n=8
M 2, n=11
M 6, n=1
M 0, n=1
M 1, n=1
Figure. Frequency of FAB types in AML patients (n = 52)
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cytogenetic abnormalities. Findings of cytogenetic results
and their association with various FAB sub groups are
shown in Table 1.
Eleven patients did not receive treatment either
because of their death even before the start of chemothera-
py or due to other reasons. Among the 41 treated patients,
21 (51.2%) achieved CR with induction chemotherapy.
According to cytogenetics, the favourable risk group 3/3
(100%) achieved complete remission (CR) while the same
was achieved by 15/32 (46.9%) in intermediate risk group
and 3/6 (50%) in unfavourable risk group Table 1.
Prognostic value of other initial parameters on the
achievement of CR was also analyzed by univariate analy-
sis. Results are shown in Table 2. Significant lower CR was
found in patients with a high white cell count whereas other
factors revealed no prognostic value in our study.
Discussion
The importance of cytogenetic studies in neoplasia
in general and in leukaemias in particular has been univer-
sally accepted. For the last two decades, it has been appre-
ciated that diagnostic cytogenetics provide one of the most
valuable prognostic indictors in AML.14-15 However, many
studies on which such conclusions drawn were compro-
mised to a variable extent either by relatively small sample
size or by inconsistency of treatment approach. These limi-
tations resulted in undermining the employment of kary-
otype at diagnosis. Unfortunately our study also has a rela-
tively small sample size.
Table 1. Cytogenetic results and their association with FAB sub-
groups in AML Patients (n = 52) and Complete remission results by
cytogenetic risk group AML patient (n=41).
Cytogenetic results and association with FAB subgroups in AML patients
(n = 52)
Number of Patients Cytogenetic results FAB Subgroups
35 Normal Karyotype M0,M1,M2,M3,M4,
M4Eo,M5,M6,
4 Hyperdiploidy M2,M4, M4Eo
4 45,X,-Y,t(8;21)(q22;q22).     M2
45,X,-Y,t(8;21)(q22;q22).
46,XY,del(9)(p13;p24).
45,X,-X,t(8;21)(q22;q22)
t(11;17)(q23; q25)?-13q.
2 46,XX,?del(6)(q13;q14).       M3
46,XY,t(15;17)(q22;q21).
5 47,XX,+19. M4
Trisomy 8.
Trisomy 8.
45,XY,-7,del(11)(q23).
46,XX,t(6;11)(25;q22).
1 47,XX,+12. M4Eo
1 49,XY,t(2;15)(q37;q21),         M5
t(7;9)(q15;q34),+8,+10,+19.
Complete remission results by cytogenetic risk group AML patient (n=41)
Risk group No. of Patients       No. (%) achieving CR
Favourable 3 3(100%)
45,X,-Y,t(8;21)(q22;q22).
45,X,-Y,t(8;21)(q22;q22)
t(11;17) (q23;q25),?-13q.
46,XY,t(15;17)(q22; q21).
Intermediate 32 15 (46.9%)
Normal. + 8. hyperdiploidy.
46,XX,?del(6)(q13;q14).
Unfavourable 6 3 (50%)
47,XX,+19.
45,XY,-7,del(11)(q23).
49,XY,t(2,15)(q37;q21),t(7;9)
(q15;q34)+8,+10,+19.
47,XX,+12.
46,XX,t(6;11)(q25;q22).
46,XY,del(9)(p13;p24).
Table 2.  Prognostic factors associated with achievement of CR in
AML patients (n=41).
Parameter Mean Rank P value
Age (years)
CR 20.19 0.665
No CR 21.85
Sex +
CR 0.536
No CR
Haemoglobin (g/dl)
CR 20.57 0.821
No CR 21.45
White cell count 109/L
CR 15.48 0.002
No CR 26.80
Platelet count 109/L
CR 21.79 0.675
No CR 20.18
+ X2 - test applied
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In the present study, abnormal karyotype was seen in
32.7% patients with denovo AML. Most studies reported an
abnormal karyotype between 54-78% of patients16,17
although both lower18 and higher19 percentages have been
reported. A study by Marcucci et al20 revealed normal kary-
otype in 45% adult denovo AML patients. Similar results
were drawn by Estey et al21 with the identical karyotypes at
diagnosis and relapse. So a stable karyotype was most fre-
quent among patients who presented without cytogenetic
abnormalities, suggesting that normal karyotype is usually
not due to sampling error. But in our study, it was not pos-
sible to do cytogenetic analysis in patients with normal
karyotype presenting with relapse or not in remission due to
financial constraints. We found t(8;21) in 3 cases of M2 and
t(15,17) in one case of M3 subtypes.
But t(16;16) or inv (16) was not found in any case.
The yield is low when compared with international studies.
The reason for these findings is not known, probably due to
inexperience particularly in the recognition of subtle struc-
tural aberrations that can sometimes be overlooked, partic-
ularly in preparation of sub-optimal quality. A study by
Grimwade et al22 reported 7 cases of APML lacking
t(15;17) on conventional cytogenetic assessment. In 6 of 7
cases, cryptic PML-RARa rearrangements were identified
by reverse transcriptase polymerase chain reaction (RT-
PCR) and fluorescent insitu hybridization (FISH). In the
remaining one case variant translocation, t(11;17) was iden-
tified. Frohling et al23 detected inv (16)/t(16;16) in 4 cases
using FISH. Veldman et al24 used multicolour spectral kary-
otype (SKY) in 15 cases with unidentified chromosome
aberrations. So molecular cytogenetics should also be con-
sidered in cases with insufficient yields of metaphase cells,
poor chromosome morphology and normal karyotype.
Most studies reported over all response to induction
chemotherapy (expressed by the CR rate) between 70 to
80% using conventional protocol with cytarabine and
daunorubicin or cytarabine and escalated doses of daunoru-
bicin and etoposide.11,18,25 Our study has comparatively a
lower rate of overall response to induction chemotherapy
which is probably due to small number of patients or
delayed referral of patients to a tertiary care centre. Various
international studies reported 80-90% CR in favourable
groups2,11,15 while 70-80% in the intermediate group and
50-60% in the unfavourable group.2,11 However a study by
Pelloso et al.15 showed 20% and 12.5% CR in the interme-
diate and the unfavourable groups respectively. Our results
in the favourable and unfavourable groups are in accordance
with these studies.2,11 However, our intermediate group
showed lower remission rate compared to some studies2,11
but the results were better, than that reported by Pelloso et
al.15 The differences in CR in various risks groups from
present study is partly due to small number of patients in
various groups or it may to be due to improved and inten-
sive chemotherapy protocols and good supportive care.
However, in the present study, favourable risk group
showed higher7 remission rates2 when compared to interme-
diate and unfavourable risk groups. This clearly establishes
diagnostic karyotype as one of the most important prognos-
tic factor for outcome of treatment in patients with AML. In
patients with normal karyotype on conventional cytogenet-
ics, sophisticated techniques should be applied to find sub-
tle changes. A large number of patients with long term fol-
low up and multicenter studies are needed for comparison of
cytogenetic results and outcome of treatment with interna-
tional studies.
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